Immunovant, Inc.
A clinical-stage biopharmaceutical company developing experimental antibody medicines for autoimmune diseases, where the body's own defenses attack healthy tissue. Its drug candidates, like batoclimab, work by lowering the harmful antibodies that drive these conditions. Immunovant was founded in 2018 within the Roivant Sciences family and went public in 2019 through a merger. Its name blends "immuno," for immunology, with the "-vant" suffix that Roivant gives all its specialized subsidiaries.
Item 4 is hereby amended by adding the following to the end thereof: Roivant purchased an aggregate of 16,666,666 shares of Common Stock in the Offering to provide further capital to the Issuer for the advancement of the Issuer's development pipeline, working capital and other general corporate purposes, as well as to increase its ownership interest in the Issuer following the Offering. As the Issuer's largest shareholder, Roivant may provide additional financing to the Issuer from time to time in the form of an investment in equity or debt securities of the Issuer or loans, including in connection with business development transactions or financing commitments in relation thereto.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Deep Track Capital, LP | 13G/APassive | 4.55% | 9.34M | Aug 14, 2026 |
| Deep Track Biotechnology Master Fund, Ltd. | 13G/APassive | 4.55% | 9.34M | Aug 14, 2026 |
| David Kroin | 13G/APassive | 4.55% | 9.34M | Aug 14, 2026 |
| Roivant Sciences Ltd. | 13D/AActivist | 55.9% | 113.33M | Dec 12, 2025 |
Item 4 is hereby amended by adding the following to the end thereof: Roivant purchased an aggregate of 16,666,666 shares of Common Stock in the Offering to provide further capital to the Issuer for the advancement of the Issuer's development pipeline, working capital and other general corporate purposes, as well as to increase its ownership interest in the Issuer following the Offering. As the Issuer's largest shareholder, Roivant may provide additional financing to the Issuer from time to time in the form of an investment in equity or debt securities of the Issuer or loans, including in connection with business development transactions or financing commitments in relation thereto. | ||||
| FMR LLC | 13G/APassive | 8.4% | 14.73M | Nov 5, 2025 |
| Abigail P. Johnson | 13G/APassive | 8.4% | 14.73M | Nov 5, 2025 |